GGrantIndex
Sort

4,870 grants matching glp 1

CNS MEDIATION OF VISCERAL ILLNESS

$201,146
University Of Cincinnati · R01 · FY2000 · DK

Problematic avoidant/restrictive eating in adults with functional dyspepsia: the role of endogenous oxytocin and glucagon-like peptide 1

$201,000
Helen Burton Murray · Massachusetts General Hospital · R03 · FY2025 · DK

Translational Biomarker Analytical Core (TBAC)

$200,882
Blandine B Laferrere · Columbia University Health Sciences · P30 · FY2022 · DK

Translational Biomarker Analytical Core (TBAC)

$200,880
Blandine B Laferrere · Columbia University Health Sciences · P30 · FY2020 · DK

Translational Biomarker Analytical Core (TBAC)

$200,880
Blandine B Laferrere · Columbia University Health Sciences · P30 · FY2021 · DK

Translational Biomarker Analytical Core (TBAC)

$200,880
F. Xavier Pi-Sunyer · Columbia University Health Sciences · P30 · FY2019 · DK

ADMINISTRATION OF GLP 1 BY SUBCUTANEOUS DELIVERY--DETERMINATION OF DOSE

$200,768
Massachusetts General Hospital · M01 · FY2001 · RR

ADMINISTRATION OF GLP 1 BY SUBCUTANEOUS DELIVERY--DETERMINATION OF DOSE

$200,768
Massachusetts General Hospital · M01 · FY2002 · RR

ADMINISTRATION OF GLP 1 BY SUBCUTANEOUS DELIVERY--DETERMINATION OF DOSE

$200,768
Massachusetts General Hospital · M01 · FY2002 · RR

Meal Frequency/Composition Effects on Insulin Resistence in Obese Individuals

$200,717
Jill A Kanaley · University Of Missouri-Columbia · R21 · FY2010 · DK

Anti-obesity pharmacotherapy to decrease BMI and improve insulin sensitivity in adolescents with obesity and type 2 diabetes

$200,620
Megan O Bensignor · University Of Minnesota · K23 · FY2023 · DK

Anti-obesity pharmacotherapy to decrease BMI and improve insulin sensitivity in adolescents with obesity and type 2 diabetes

$200,620
Megan O Bensignor · University Of Minnesota · K23 · FY2022 · DK

Anti-obesity pharmacotherapy to decrease BMI and improve insulin sensitivity in adolescents with obesity and type 2 diabetes

$200,620
Megan O Bensignor · University Of Minnesota · K23 · FY2024 · DK

Anti-obesity pharmacotherapy to decrease BMI and improve insulin sensitivity in adolescents with obesity and type 2 diabetes

$200,620
Megan O Bensignor · University Of Minnesota · K23 · FY2025 · DK

A new condom design for encouraging correct and consistent use

$200,601
Stacy L Chin · Hydroglyde Coatings, Llc · R43 · FY2016 · HD

Automated Intestinal Electrical Stimulation for Diabetes

$200,330
Jiande Chen · Transtimulation Research, Inc. · R43 · FY2013 · DK

Meal Frequency/Composition Effects on Insulin Resistence in Obese Individuals

$200,041
Jill A Kanaley · University Of Missouri-Columbia · R21 · FY2009 · DK

Intestinal satiation in Roux-en-Y gastric bypass rats: brain mechanisms and sex d

$200,000
Loredana Asarian · University Of Zurich · R01 · FY2011 · DK

Protection and Treatment of the Ocular Surface Barrier

$199,860
M. Elizabeth Fini · Proteris Biotech, Inc. · R41 · FY2016 · EY

Translational Biomarker Analytical Core (TBAC)

$199,846
F. Xavier Pi-Sunyer · Columbia University Health Sciences · P30 · FY2018 · DK

Targeted Nanoparticles of Bismuth Organo Complexes for Spectral CT Imaging of Cor

$199,770
Y Andrew Wang · Ocean Nanotech, Llc · R42 · FY2012 · HL

TAS::75 0849::TAS

$199,757
Barbara Olszewska-Pazdrak · Chrysalis Biotherapeutics, Inc. · N43 · FY2011 · CA

Experimental Mouse

$199,698
Natalia A Ignatenko · University Of Arizona · P30 · FY2019 · CA

Phase 1 Study of VSV-hIFN-B for the Treatment of Hepatocellular Carcinoma

$199,522
Mitesh Borad · Mayo Clinic Arizona · R01 · FY2014 · FD

An Improved Method of Delivering a Sclerosing Agent for the Treatment of a Malignant Pleural Effusion.

$199,347
Glenn W Laub · Tdl Innovations, Llc · SB1 · FY2021 · CA